MYO - Myomo, Inc.
| Previous Close | 0.3198 |
| Open | 0.3104 |
| Bid | 0.3050 x 1800 |
| Ask | 0.3074 x 1000 |
| Day's Range | 0.3000 - 0.3149 |
| 52 Week Range | 0.2600 - 1.8000 |
| Volume | 83,266 |
| Avg. Volume | 226,925 |
| Market Cap | 5.289M |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6900 |
| Earnings Date | Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.35 |
- Zacks
Teleflex's Bipolar Temporary Pacing Guidewire Gets FDA Nod
Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.
- Zacks
Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent developments.
- Zacks
Medtronic (MDT) Gets FDA Nod for Micra AV to Treat AV Block
Medtronic's (MDT) Micra AV cleared by the FDA for the treatment of AV block in patients eligible for pacemaker implantation.
- Business Wire
Myomo Announces Partnership with Hobbs Rehabilitation for UK
Myomo®, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has formed a partnership with Hobbs Rehabilitation to provide a range of services to support MyoPro® users in the UK. Hobbs neurological physiotherapists and occupational therapists will work with patients using the Myomo family of myoelectric orthotics and have already been using Myomo devices to treat patients with upper limb paralysis as part of their intensive rehabilitation packages.
- Zacks
Myomo, Inc. (MYO) Reports Q3 Loss, Misses Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 0.00% and -53.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Myomo Reports Third Quarter 2019 Results
Growth Metrics Accelerating; Timing of Insurance Payments Affecting Short-term Revenue Growth
- Business Wire
Myomo to Report Third Quarter 2019 Results on November 12, 2019
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it will release its financial results for the third quarter ended September 30, 2019 on Tuesday, November 12, 2019, after the market close. The Company will host a conference call the same day, Tuesday, November 12, 2019 at 4:30 p.m. ET with prepared remarks by Paul R. Gudonis, Chairman and Chief Executive Officer, and David Henry, Chief Financial Officer. The conference call webcast can be accessed through Myomo’s Investor Relations page at http://ir.myomo.com/.
- Zacks
Myomo, Inc. (MYO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
Myomo Closes $3M Term Loan
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced that it has entered into a term loan agreement with Chicago Venture Partners (CVP) for $3 million. Myomo expects to use the proceeds to continue to grow the company’s pipeline of qualified MyoPro candidates, introduce the new pediatric version of its MyoPro orthosis, and for general corporate purposes.
- Business Wire
Myomo Announces Departure of Steve Sanghi from Board of Directors
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced the resignation of Steve Sanghi from its Board of Directors to focus on his duties as CEO and Board Chairman of Microchip Technology Inc. He will continue to serve as an advisor to Myomo and remain a personal investor in the company.
- Simply Wall St.
Here's Why We're A Bit Worried About Myomo's (NYSEMKT:MYO) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- Zacks
GNC Holdings Inks Retail Partnership Deal to Grow in Brazil
We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.
- Zacks
Innovation Aids Genomic Health, Merger Procedure on Track
Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.
- Zacks
Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
Insulet (PODD) has various favorable factors to maintain the current high.
- Simply Wall St.
Before You Buy Myomo, Inc. (NYSEMKT:MYO), Consider Its Volatility
If you own shares in Myomo, Inc. (NYSEMKT:MYO) then it's worth thinking about how it contributes to the volatility of...
- Zacks
Will Myomo, Inc. (MYO) Report Negative Q2 Earnings? What You Should Know
Myomo, Inc. (MYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.
If You Had Bought Myomo (NYSEMKT:MYO) Stock A Year Ago, You'd Be Sitting On A 73% Loss, Today
Even the best investor on earth makes unsuccessful investments. But serious investors should think long and hard about...
- Business Wire
Myomo Announces First Insurance Reimbursements in European Markets
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announced today that its Orthotics and Prosthetics (O&P) distribution partners in Germany and Denmark have successfully obtained their first reimbursement decisions by insurance payers for the MyoPro orthosis. In addition, these O&P providers, along with other certified firms in the UK and Italy, have a growing number of MyoPro units in the reimbursement process.
- Simply Wall St.
What Percentage Of Myomo, Inc. (NYSEMKT:MYO) Shares Do Insiders Own?
The big shareholder groups in Myomo, Inc. (NYSEMKT:MYO) have power over the company. Large companies usually have...
- Business Wire
Myomo® Announces Participation in Beijing Trade Show
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, announces its participation in the China International Fair for Trade in Services, to be held in Beijing from May 28-31, 2019. Myomo will participate in this event together with Beijing Ryzur Medical Investment Co., Ltd. (Ryzur Medical), a growing medical device manufacturer based in Beijing.
